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http://dx.doi.org/10.1016/j.tmaid.20Summary With the aim to identify at-risk individuals among a cohort of international travel-
lers, 3442 individuals who sought advice at Marseille travel health centre in 2009 were prospec-
tively included. Demographics, travel characteristics, chronic medical conditions, vaccinations
and antimalarial chemoprophylaxis were documented.
Chronic medical conditions were reported by 11% of individuals, including hypertension
(39%), asthma (20%), thyroid disease (15%) and depression (13%). 4% reported taking a daily
medication, and psychotropic and cardiovascular medications were the most commonly used.
Older travellers (60 years) accounted for 10% of the travellers and the prevalence of chronic
medical conditions was 27% in this group. Individuals aged 15 years or less accounted for 13% of
the travellers. Age, last minute travel (17%) and neurological and psychiatric diseases were the
most frequent factors that influenced Yellow fever vaccination and malaria chemoprophylaxis,
with more than one tenth of the travellers reporting at least one risk factor for which adjusted
advice may be necessary. Migrants visiting their relatives in their origin country accounted for
14% of travellers and 73% of this group travelled with their family including young children.
We demonstrate that a significant proportion of travellers are at-risk (43%) because of their
travel conditions (VFR), their age, or their health status, and should be targeted for risk reduc-
tion strategies.
ª 2012 Elsevier Ltd. All rights reserved.) 4 91 96 35 35; fax: þ33 (0) 4 91 96 89 38.
club-internet.fr (P. Gautret).
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Figure 1 Number of visits and travel departure per month of
3442 travellers from Marseille, in 2009e2010.
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Over 80 million people travel annually from industrialised
countries to the developing world, and this trend continues
to increase.1 European travellers account for the majority
of international travellers, and travel-associated diseases
are frequent among this mobile population.2 In 2006, 22.5
million French citizens travelled abroad to the following
countries: Europe (33%), North Africa (12%), Asia (7%), the
Caribbean (4%), Latin America (2%), the Indian Ocean (2%),
Sub-Saharan Africa (2%), the Middle East (1%) and Oceania
(1%).3 A total of 120 countries were visited, of which one
out of four were considered to be at high-risk for travel-
associated diseases.3 This risk is notable for infectious
diseases that are associated with food and water
consumption, arthropod bites, environmental conditions
and sexual behaviour and is frequently underestimated by
travellers. In a study that was conducted in airports in
Europe of travellers to tropical countries, only 50% of
travellers had sought pre-travel advice and only one-third
of travellers to malaria-endemic countries took antima-
larial chemoprophylaxis.4 In France, a telephone survey
that was conducted among individuals 18e79 years of age
revealed that 75% of respondents considered it useful to
seek medical advice prior to travelling, but only 63% of the
respondents sought advice.5 Because of the increasing
number of international travellers to at-risk destinations,
pre-travel advice is a key point in a public health
perspective, which limits the burden of travel-associated
diseases in French travellers and the risk of importation
of communicable diseases in France. Over 100 specialised
pre-travel clinics were recorded in a national survey that
was conducted in 2009 in France, of which five clinics were
in the Bouches du Rhoˆne district in Southern France
(1,995,094 inhabitants in 2009), including three clinics in
the largest city, Marseille (858,902 inhabitants in 2009).6
Published data regarding the characteristics of French
travellers are scant and limited to specific categories of
travellers or specific travel destinations.7e9 With the aim to
identify at-risk travellers departing from Marseille, we
conducted a study on individuals who sought advice at
a travel health centre in 2009.
Materials and methods
Study travellers
All of the travellers who presented to the travel health
centre at a tertiary care hospital (University Institute for
Infectious and Tropical Diseases, Marseille) were included
prospectively in a study from January 2009 to December
2009. Travellers to Mecca who were participating in the
Hajj were excluded because a specific survey was con-
ducted in this population.10 In addition, travellers who
were consulted for a systematic vaccination for business
travel with no specific travel destination (air and navy
crew) were excluded. A total of 8 medical doctors docu-
mented the demographics (gender, age, and socio-
professional category according to the INSEE classifica-
tion11), travel characteristics (visit date, departure date,
countries travelled to, travel duration, reason for travel,number of co-travellers, and risk level) and medical
conditions (chronic diseases, treatments, and pregnancy).
Additionally, prescribed vaccinations and antimalarial
chemoprophylaxis were documented. The factors that
influenced standard pre-travel health advice were docu-
mented according to the Van de Winkel criteria addressing
condition with possible interaction with malaria prevention
and Yellow fever vaccination, and preventive measures for
travellers’ diarrhoea and other enteric infections. Details
about what constitutes a possible interaction or a possible
influencing factor are described elsewhere.12
Statistical analysis
The data were entered anonymously and managed in the
SPSS software package, v16.0 (SPSS Inc., Chicago). The
differences in the proportions (categorical variables) were
tested by Fisher’s exact tests, and the differences in the
medians (continuous variables) were tested by the Krus-
kaleWallis test. p Values <0.05 were considered statisti-
cally significant.
Results
Traveller and travel characteristics
A total of 3957 travellers presented to the centre over the study
period, of whom 479 (11.8%) were Hajj pilgrims and 36 (0.9%)
were air and navy crew. A total of 3442 travellerswere included
in the study. The mean number of visits per month was 285
(Fig. 1). There was a 1.4 fold increase in the number of visits in
June and a 1.2 fold increase in July due to departures for
summer scholar vacations. A decrease in the number of visits
was observed in April, May and August for internal reasons and
in October because most of the consultants were Hajj pilgrims
during this month. The M/F sex ratio was 0.98, and the mean
age was 36.6 years (range Z 1 monthe85 years). Individuals
who were 18 years of age accounted for 14.9% of the travel-
lers, including 459 children 15 years of age and 48 children
one year of age. Older travellers who were 60 years of age
accounted for 10.4% of the travellers (Table 1). Among the
travellers >18 years of age, 62.0% of the socio-professional
Table 1 Demographics and travel characteristics of 3442 travellers from Marseille, according to reason for travel in 2009.
All travellers N (%) Tourists N (%) Business
travellers N (%)
VFRsa N (%)
Gender Male 1709 (49.6) 925 (46.9) 392 (69.3) 211 (47.8)
NDb 3 1 0 1
Age (years) 0e17 504 (14.9) 235 (12.1) 39 (7.0%) 173 (39.5)
18e59 2533 (74.7) 1445 (74.7) 481 (86.7%) 240 (54.8)
>60 352 (10.4) 255 (13.2) 35 (6.3%) 25 (5.7)
ND 53 35 11 3
Socio-professional
category (18 years
of age)
Farmer 4 (0.2) 3 (0.3) 1 (0.3) 0 (0.0)
Contractor/
Craftsman
95 (5.3) 46 (4.2) 33 (9.6) 7 (5.7)
Business executive 425 (23.7) 250 (22.8) 129 (37.4) 10 (8.2)
Intermediate
profession
472 (26.4) 298 (27.2) 101 (29.3) 29 (23.8)
Employee 241 (13.5) 155 (14.1) 47 (13.6) 23 (18.9)
Factory worker 29 (1.6) 11 (1.0) 12 (3.5) 7 (5.7)
Retired 251 (14.0) 206 (18.8) 6 (1.7) 18 (14.8)
Student/
Unemployed
272 (15.2) 128 (11.7) 16 (4.6) 28 (23.0)
Travelled regions Africa 2252 (65.8) 1150 (58.7) 391 (70.1) 394 (89.3)
America 638 (18.6) 441 (22.5) 98 (17.6) 30 (6.8)
Asia 485 (14.2) 337 (17.2) 59 (10.6) 17 (3.9)
Oceania 14 (0.4) 3 (0.2) 9 (1.6) 0 (0.0)
Europe 1 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Round the world 33 (1.0) 29 (1.5) 1 (0.2) 0 (0.0)
ND 39 13 8 0
Travelled countries
(top 10)
Senegal 657 (21.6) Senegal 474
(25.9)
French Guyana 61
(11.6)
Comoros 112
(25.5)
Kenya 187 (6.1) Kenya 170 (9.3) Gabon 45 (8.6) Senegal 83 (18.9)
Brazil 161 (5.3) Brazil 116 (6.3) Senegal 38 (7.2) Coˆte d’ivoire
38 (8.6)
Burkina Faso
154 (5.1)
Tanzania 77 (4.2) Mali 37 (7.0) Madagascar
27 (6.1)
French Guyana
151 (5.0)
India 76 (4.2) Coˆte d’ivoire
35 (6.7)
Guinea 16 (3.6)
Mali 147 (4.8) Peru 74 (4.0) Cameroun
32 (6.1)
Burkina Faso
16 (3.6)
Comoros 127 (4.2) Thailand 72 (3.9) Congo 26 (4.9) French Guyana
16 (3.6)
Coˆte d’ivoire
121 (4.0)
Mali 67 (3.7) Angola 25 (4.8) Cameroun
14 (3.2)
India 95 (3.1) Burkina Faso
65 (3.6)
South Korea
24 (4.6)
Benin 13 (3.2)
Tanzania 86 (2.8) French Guyana
65 (3.6))
Burkina Faso
22 (4.2)
Gabon 13 (3.2)
Number of countries
per travel
1 country 3105 (90.9) 1780 (90.4) 512 (91.9) 435 (98.9)
>1 country 278 (8.1) 152 (7.7) 45 (8.1) 5 (1.1)
Round the world 33 (1.0) 29 (1.5) 0 (0.0) 0 (0.0)
ND 39 12 8 0
Mean travel duration
(weeks)
1 495 (15.4) 313 (16.4) 138 (27.6) 11 (2.6)
1e2 1224 (38.1) 969 (50.7) 82 (16.4) 81(19.3)
>2e4 733 (22.8) 429 (22.3) 57 (11.4) 150 (35.7)
>4e12 426 (13.3) 118 (6.3) 62 (12.2) 166 (39.3)
>12e36 126 (3.9) 37 (1.9) 48 (9.6) 3 (0.7)
>36e52 76 (2.3) 24 (1.2) 47 (9.6) 2 (0.7)
>52 135 (4.2) 22 (1.2) 66 (13.2) 7 (1.7)
ND 226 61 66 21
(continued on next page)
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Table 1 (continued )
All travellers N (%) Tourists N (%) Business
travellers N (%)
VFRsa N (%)
Reason for travel Tourism 1970 (60.3)
Business 566 (17.3)
VFR 440 (13.5)
Humanitary 179 (5.5)
Family
regroupment
2 (0.1)
Study 77 (2.4)
Adoption 12 (0.4)
Resident 12 (0.4)
Military 6 (0.2)
Sport 2 (0.1)
Expulsion 1 (0.0)
ND 170
Number of
co-travellers
Group 952 (34.5) 634 (36.6) 150 (36.5) 23 (6.4)
Family 884 (32.0) 509 (29.4) 73 (17.8) 263 (73.3)
Pair 530 (19.2) 447 (25.8) 29 (7.2) 27 (7.5)
Solo 394 (14.3) 144 (8.2) 159 (38.7) 46 (12.8)
ND 680 239 155 82
Risk level Pre-organised tripc 1565 (85.7) 1181 (77.4) 209 (56.3) 72 (24.5)
Risk traveld 134 (7.3) 342 (22.4) 69 (18.6) 217 (73.8)
Expatriate 127 (7.0) 2 (0.1) 93 (25.1) 5 (1.7)
ND 1010 448 195 147
a VFRs Z visiting friends and relatives.
b ND Z non documented. % were calculated for documented data only.
c Pre-organised trip intended to identify travellers who are sheltered or “cocooned” from many of the risks (food, vectors, sleeping
conditions) faced by the local population. Uses the infrastructure of the travel industry (includes internet self-booking) in the home
country for most or all arrangements. Uses standard or better hotel or other short-stay temporary accommodation. Eats mostly at
restaurants serving large numbers of foreigners and which is often pre-screened by tour operators or employers. Uses mostly in-country
transportation specifically serving tourists or foreigners.
d Risk travel: intended to identify travellers who will, by their behaviour, encounter a substantial number of the risks facing the local
population. This classification would generally include no pre-booking of accommodation for most or all nights and/or use of accom-
modation specific to budget travellers or those staying in the house of local residents.
250 C. Aubry et al.categories were documented. Of these travellers, 70.7% were
working currently, 14.0%were retired and 15.2%were students
or unemployed. Of 10 travellers, 7 planned to travel to Africa, 2
to the American continent and 1 to Asia. The top 10 visited
countries were Senegal, Kenya, Burkina Faso, French Guyana,
Mali, Comoros, Coˆte d’Ivoire, India and Tanzania. Overall,
90.9% of the travellers planned to visit only one country. The
mean travel duration for individuals who were travellingone
year (95.8%)was5.6weeks (rangeZ0.1e52weeks). The travel
durationwas2weeks for 53.5% of the travellers,onemonth
for 76.3%, >3 months for 10.4% and >six months for 6.5%. The
mean time between the visit date and the departure date was
32.4 days (range Z 0e269 days), and 17.2% of the travellers
were consulted10 days before departing, 44.8%21 days and
57.4% 28 days. The most common reasons for travel were
tourism, business and visiting friends and relatives (VFR). The
majority of travellers travelled at least by pair and underwent
pre-organised trips.
The demographics and travel characteristics varied
according to the reason for travel. Tourists and business
travellers were older than VFRs (37.6 and 38.9 years of age
vs. 26.3 years of age, p <0.001). Africa was the most
common destination among the three groups of travellers.
Overall, 69.4% of the travellers the American continent and71.5% of the travellers to Asia were tourists. The top 3
visited countries were Senegal, Kenya and Brazil among
tourists; French Guyana, Gabon and Senegal among
business travellers; and Comoros, Senegal and Coˆte d’Ivoire
among VFRs. Tourists had a shorter travel duration
(4.0 weeks, range Z 0.5e52 weeks) compared to VFRs
(5.2 weeks, rangeZ 0.3e40 weeks) and business travellers
(10.4 weeks, rangeZ 0.1e52 weeks) with p <0.001. Tourist
travellers were less likely to travel with their families
compared to VFRs (32.0% vs. 73.3%), and tourists and
business travellers underwent pre-organised trips more
frequently compared to VFRs (77.4% and 56.3% vs. 24.5%)
with p <0.001.
Medical conditions
Among female travellers 16e50 years of age (N Z 1091,
63.0% of female travellers), eight travellers were pregnant,
18 were trying to conceive and two were breastfeeding.
One or more medical conditions were identified in 11.3% of
the travellers (Table 2). The mean age of travellers with
chronic medical conditions was 45.1 years, and the M/F sex
ratio was 1.3. The prevalence of chronic medical conditions
was 27.0% in travellers 60 years of age, 9.9% in travellers
Table 2 Chronic medical conditions in 3442 travellers from Marseille in 2009.
Syndrome (N ) Disease Travellers
(N )
% of ill
travellers
% of all
travellers
Cardiovascular (215) Hypertension 150 38.6 4.6
Myocardial infarction/Angor 29 7.5 0.9
Heart rhythm and conduction disorder 13 3.3 0.4
Thromboembolic disease 9 2.3 0.3
Cardiopathy 2 0.5 0.1
Valvular disease 3 0.8 0.1
Other 3 0.8 0.1
Endocrinology (109) Thyroid disease 57 14.7 1.7
Diabetes 45 11.6 1.4
Dyslipidemiae 15 3.9 0.5
Other 7 1.8 0.2
Respiratory (87) Asthma 77 19.8 2.4
Cystic fibrosis 2 0.5 0.1
Other (Quincke oedemaerhinitis) 6 1.5 0.2
Psychiatric (53) Depression 49 12.6 1.5
Other (anxietyepsychosiseautism) 3 0.8 0.1
Cancer (36) Cancer 37 9.5 1.1
Neurologic (36) Migraine 16 4.1 0.5
Epilepsy 12 3.1 0.4
Stroke 7 1.8 0.2
Other (Guillain Barre´emultiple
sclerosisemyastheniaemyelitis)
4 1.0 0.1
Gastrointestinal diseases (32) Crohn’s disease 7 1.8 0.2
Ulcerative colitis 4 1.0 0.1
Other (gastric ulcerediarrhoea-irritable
bowel syndrome)
21 5.4 0.6
Rheumatologic (19) Inflammatory joint disease 7 1.8 0.2
Senescent arthritis 4 1.0 0.1
Others (HystiocytosiseSclerodermiaeBullous
pemphygoideDeficit IgA.eLupus)
8 2.1 0.2
Infectious diseases (18) Hepatitis C 7 1.8 0.2
HIV infection 4 1.0 0.1
Hepatitis B 4 1.0 0.1
Other (infected hip
prostheseseurinary infection)
3 0.8 0.1
Pediatrics (13) Bronchiolitis 4 1.0 0.1
Premature 4 1.0 0.1
Gastro-oesophageal reflux disease 3 0.8 0.1
Febrile seizure 2 0.5 0.1
Cow milk protein allergy 1 0.3 0.0
Blood diseases (12) Coagulation disorder 6 1.5 0.2
Sickle cell anaemia 3 0.8 0.1
Splenectomy 2 0.5 0.1
Thrombocytopenic purpura 1 0.3 0.0
Dermatologic (11) Atopic dermatitis 5 1.3 0.2
Eczema 3 0.8 0.1
Acnea 3 0.8 0.1
Renal diseases (7) Kidney transplant 3 0.8 0.1
IgA nephropathy, chronic renal
dysfunction, Polycystic kidney disease
4 1.0 0.1
Ophthalmologic (6) Glaucoma 6 1.5 0.2
Hear, Ear Eye, Nose, Throat (6) (Vertigo. Neurinoma. Cholesteatoma) 9 2.3 0.3
Gynaecologic (4) Endometriosis 4 1.0 0.1
Urologic (4) Benign prostatic hyperplasia,
Renal stone disease, Nephrectomy
4 1.0 0.1
Rare diseases (2) Tuberous sclerosis, Tinu syndrome,
Proteus syndrome
3 0.5 0.1
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Table 3 Malaria risk and malaria prophylaxis according to reason for travel of 3442 travellers from Marseille, according to
reason for travel in 2009.
All travellers N (%) Tourists N (%) Business travellers N (%) VFRsa N (%)
Malaria risk Type 1 and 2b 1087 (33.8) 734 (40.0) 179 (34.0) 55 (12.5)
Type 3b 2132 (66.2) 1100 (60.0) 349 (66.0) 384 (87.5)
NDc 222 139 38 2
Antimalarial Doxycycline 708 (37.2) 265 (26.7) 114 (36.8) 189 (53.5)
Mefloquine 127 (6.7) 33 (3.3) 11 (3.5) 70 (19.8)
AtovaquoneeProguanil 963 (50.6) 665 (67.2) 143 (46.1) 78 (22.1)
ChloroquineeProguanil 18 (0.9) 1 (0.1) 3 (1) 8 (2.3)
None 88 (4.6) 27 (2.7) 39 (12.5) 8 (2.3)
ND 103 109 39 31
a VFRs Z visiting friends and relatives.
b Type 1 Z absence of Plasmodium falciparum strains resistant to chloroquine, Type 2 Z presence P. falciparum strains resistant to
chloroquine, Type 3 Z High prevalence of P. falciparum strains resistant to chloroquine and multi-resistant strains.13
c ND Z non documented. % were calculated for documented data only.
252 C. Aubry et al.18e59 years of age and 7.3% in travellers <18 years of age.
The most frequent diseases were hypertension, asthma,
thyroid diseases, depression and diabetes. The most
frequent treatments were cardiovascular and psychotropic
medications, which were most commonly used by travellers
60 years of age compared to those 18e59 years of age.
In total, 29 (0.8%) travellers were immunocompromised
(18 travellers because of a chronic disease and 11 travellers
because of immunosuppressive drug intake).
Malaria chemoprophylaxis and vaccines
Overall, 70.7% of travellers received malaria chemopro-
phylaxis, mainly atovaquone/proguanil and doxycycline.
Two-thirds of travellers travelled to areas where the prev-
alence of chloroquine resistance was high or where multi-
resistance was present (group 3 according to the 2009
French classification),13 of whom 50.6% received atova-
quoneeproguanil, 37.2% doxycycline and 6.7% mefloquine
(Table 3). Few travellers were prescribed chloroquine/
proguanil, most of them travelling to South India and
Madagascar. The choice of antimalarial drug was dependent
on the duration of travel (Fig. 2). According to the 2009
French recommendations13, a total of 2489 (72.3%)0
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Figure 2 Number of travellers receiving doxycycline,
mefloquine or atovaquoneeproguanil according to duration of
travel, in weeks of 3442 travellers from Marseille, in 2009.travellers had an indication for Yellow fever vaccine. In 23
cases, the vaccination was contraindicated (12 children less
than nine months of age, five pregnant women, and seven
travellers with immunocompromising conditions). Overall,
two-thirds of travellers were immunised previously against
tetanus, diphtheria and poliomyelitis (TDP) (Table 4).
Tourist travellers were significantly more likely to be
immunised against TDP compared to business travellers and
VFRs (p Z 0.009). One-third of travellers were immunised
against hepatitis B with no significant differences according
to the reason for travel. By contrast, VFRs were signifi-
cantly less likely to be vaccinated against hepatitis A and
typhoid fever before their visit to the clinic and were less
likely to receive vaccines against these diseases during the
visit compared to other travellers (p < 0.001). Age, last
minute travel and neurological and psychiatric diseases
were the most frequent factors that influenced Yellow
fever vaccination and malaria chemoprophylaxis (Table 5).
Discussion
The mean age (37 years) of the travellers and the
predominance of tourists in our survey is similar to the
findings of another study that was conducted in Paris7 and
of international studies that were conducted in travel
clinics.14e18 In our survey, >30% of travellers were business
travellers or VFRs, whereas these categories accounted for
11.2%e36.1% in other studies.7,14,15,17 The travellers who
were seen in Marseille was characterised by the predomi-
nance of travel destinations to Sub-Saharan Africa, which
may reflect the past colonial history of France and subse-
quent migration waves, notably in South France. In 2008,
46.4% of travellers who were consulted at a travel clinic in
Paris had a destination to Asia and 39.5% of travellers to
Africa.7 South America was the main destination of travel-
lers in a study in Spain,15 whereas Thailand was the main
destination in a study in Sweden16 and India was the main
destination in a study in the U.S.14 Vaccination coverage
against tetanus and diphtheria in the travellers in Marseille
was similar to that of other surveys,14 whereas the vacci-
nation coverage against hepatitis B was lower.14,17,18 This
low vaccination rate against hepatitis B reflects the well-
Table 4 Immunisation status before visit and vaccination provided during visit according to reason for travel of 3442 travellers
from Marseille, according to reason for travel in 2009.
Vaccine All travellers Tourists Business travellers VFRsa
Immunisationb
N (%)
Vaccination
N (%)
Immunisation
N (%)
Vaccination
N (%)
Immunisation
N (%)
Vaccination
N (%)
Immunisation
N (%)
Vaccination
N (%)
TDPc 2225 (64.6) 681 (19.8) 1313 (66.5) 393 (19.9) 344 (60.8) 136 (24.0) 269 (61.0) 85 (19.3)
HepBd 1077 (31.3) 142 (4.1) 589 (29.9) 58 (2.9) 170 (31.1) 41 (7.2) 137 (30.1) 24 (5.4)
TFe 367 (10.6) 1277 (37.1) 205 (10.4) 600 (30.4) 70 (12.4) 184 (32.5) 18 (4.1) 60 (13.6)
Hep Af 591 (17.1) 1429 (41.5) 341 (17.3) 593 (30.1) 116 (20.5) 186 (32.9) 33 (7.5) 60 (13.6)
JEg 2 (0.02) 19 (0.6) 2 (0.1) 7 (0.4) 0 (0.0) 10 (1.8) 0 (0.0) 0 (0.0)
Rabies 24 (0.7) 194 (5.6) 14 (0.7) 104 (5.2) 5 (0.8) 53 (9.3) 1 (0.2) 5 (1.0)
a VFR Z visiting friends and relatives.
b Travellers were considered immunised based on documented or self-reported previous vaccination and according to French
guidelines.13,34
c TDP Z tetanus, diphtheria, poliomyelitis.
d Hep B Z hepatitis B.
e TF Z typhoid fever.
f Hep A Z hepatitis A.
g JE Z Japanese encephalitis.
Table 5 Factors influencing yellow fever vaccination, malaria prophylaxis and traveller’s diarrhoea treatment of 3442 trav-
ellers from Marseille in 2009.
Prescription Factors N % All travellers
Yellow fever vaccination Allergy to eggs ND
Last minute travel (<10 days before departure) 427 13.2
<1 year of age 45 1.3
>60 years of age 312 9.2
Intended conception 18 0.6
Confirmed pregnancy 8 0.2
Immunocompromised traveller 14 0.4
Rheumatic disorder immunosupressive medication 2 0.1
Organ transplant immunosupressive medication 3 0.1
Immunosuppressive medication for cancer 1 0.0
Generalised eczema or psoriasis
immunosupressive medication
1 0.0
HIV infection with <200 CDþ 0 0.0
Thymoma-thymectomy 1 0.0
Malaria chemoprophylaxis Allergy to doxycycline ND
Known intolerance to antimalarials ND
Last minute travel (<10 days before departure) 427 13.2
<1 year of age 45 1.3
>60 years of age 312 9.2
Intended conception 18 0.6
Confirmed pregnancy 8 0.2
Neuropsychiatric disorder 51 1.5
Epilepsy 14 0.4
Heart rhythm and conduction disorder 14 0.4
Intake of oral anticoagulants 12 0.4
Severe renal or hepatic failure 2 0.1
Splenectomy 2 0.1
Generalised psoriasis 1 0.0
Traveller’s diarrhoea treatment Decreased gastric acid (surgery/proton
pomp inhibitors)
9 0.3
Pregnancy 8 0.2
HIV infections/AIDS 4 0.1
Allergy to fluoroquinolone ND
Crohn’s disease/ulcerative colitis 2 0.1
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254 C. Aubry et al.known reluctance of the French population towards the
hepatitis B vaccine. Therefore, the pre-travel visit is an
opportunity to provide this routine vaccine.
Our study suggests that the majority of travellers can be
given standard pre-travel advice on malaria prophylaxis,
Yellow fever vaccination, and travellers’ diarrhoea.
However, more than one tenth of the travellers reported at
least one risk factor for which adjusted advice may be
necessary.
In addition, we identified subpopulations of travellers
with specific needs, including VFRs, children, seniors, and
travellers with chronic medical conditions, accounting for
43% of the travellers (Fig. 3). Cardiovascular diseases
accounted for 50% of the travel-associated deaths in the
American travellers,19 whereas these diseases accounted
for 27% of the travel-associated deaths in French travel-
lers.20 Cardiovascular diseases are the second most
frequent cause of medical evacuations and are responsible
for 50% of the deaths among French travellers during
international flights.21 In our study, cardiovascular diseases
were the most frequent chronic conditions among the
travellers. Regarding the possible drug interactions and
cardiovascular side effects of antimalarials, travel health
specialist should be particularly cautious when advising
patients who suffer from heart rhythm and conduction
diseases or are taking anticoagulants. We recommend that
such patients would benefit from an evaluation by a cardi-
ologist before travelling. Psychiatric disorders were also
prominent among travellers, in our experience with
depression accounting for most cases, which contraindi-
cates the use of mefloquine. Senior travellers frequently
suffer from chronic diseases and take medications; there-
fore, prescriptions by travel health specialists may lead to
drug interactions or side effects in older travellers. The
proportion of older travellers will probably increase in theFigure 3 Proportion of at-risk travellers (travellers visiting friend
years)) and travellers with chronic conditions.future due to an increase in life expectancy, and a travel
medicine specialist will need to have competence in
Medicine of the Elderly. Young travellers represented
a small proportion of the travellers; however, they pose
specific challenges.22,23 Notably, there is no clear recom-
mendation in France for malaria chemoprophylaxis in
infants who weigh less than 11 kg who travel to malaria-
endemic areas where resistance to chloroquine or other
antimalarials is highly prevalent. In practice, atovaquone/
proguanil is used in infants who weigh >5 kg in Belgium,
Canada and the U.S.24 French guidelines, mention that
atovaquone/proguanil can be used in infant weighing
5e11 kg,13 however, it is off-label in France, and practi-
tioners have little protection if adverse events occur.
Mefloquine in France is not recommended in infants
weighing <15 kg, although it has proven effective and
safe25 which therefore do not offer an alternative. An
official extension of the indication of both drugs to include
use in children <11 kg could solve the dilemma. VFRs
include both migrants who are returning to their birth
country to visit their relatives and second and third
generation French-born descendants.26 VFRs account for
25e40% of the travellers to tropical areas.27 Because they
travel for longer durations often in rural areas and share
local food with their family, these travellers are particu-
larly at risk for travel-associated infectious diseases. In
2009, 70% of the malaria cases in the U.S. were observed in
VFRs.28 A similar pattern has been observed for typhoid
fever.29 Furthermore, VFRs seek pre-travel advice less
frequently than tourists.26 The Comorian community is the
largest Sub-Saharan migrant community in Marseille, which
consists of an estimated 50,000e70,000 individuals.30
However, VFRs who travel to Comoros accounted for only
4% of the travellers who were seen at our pre-travel clinic.
This finding is partly because Yellow fever vaccination is nots and relative (VFR), children (<18 years), older travellers (>60
Demographics, health and travel characteristics of international travellers 255required in Comoros; therefore, a visit to a specialised
centre is not mandatory. A visit to a general practitioner
may be more acceptable, more accessible, and possibly
preferred by this community. However, a study that was
conducted in 2003 among Comorians who suffered from
malaria upon their return from Comoros demonstrated that
most of the travellers did not use chemoprophylaxis
because of a lack of information, a belief that being born in
Comoros confers protection against malaria and the high
cost of antimalarials.31 In this context, providing more
information regarding the risk of infectious diseases may be
one way that allows travellers to prioritise their choice of
using chemoprophylaxis according to their financial
capacity. Alternatively, reimbursement of malaria prophy-
laxis by the public French national health insurance system
has been proposed32 and this may be an option for selected
at-risk travellers including those travelling to Comoros.
Conclusions
Travellers who sought advice at other travel clinics in
Marseille or from general practitioners or travellers who did
not seek advice at all were not included in our study.
Travellers to Europe and North Africa, which are preferred
destinations of French travellers, were not captured in our
survey. Notably, a study that was conducted in 2008 among
European travellers indicated that the majority of travel-
lers with respiratory infections were returning from coun-
tries in Europe, and the majority of travellers with acute
diarrhoea were returning from North Africa.33 Our results
demonstrate that travellers who sought advice at our travel
clinic are not representative of the entire travelling pop-
ulation but are representative of travellers to tropical areas
and particularly to countries at risk for Yellow fever. We
believe that the results of our survey can be extrapolated
to the French travellers who seek advice at travel clinics in
France; however, the proportion of travellers to Africa may
be overrepresented in our survey.
Our survey provides insight into the health conditions,
travel destinations, travel duration, and pre-travel medical
care of an epidemiologically significant population and
should facilitate the targeting of risk reduction strategies
for this group. Such knowledge could assist in limiting the
spread of infections that are related to international travel.
We demonstrate that a significant proportion of travellers
are at-risk (43%) because of their travel conditions (VFR),
their age, or their health status. This implies that pre-travel
advice is quite complex and we recommend that special
training should be provided to non-specialists giving pre-
travel advice. Most complex situations will be better
addressed at a specialised travel clinic.
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